Trial reportCells2021
Beneficial Effects of
Open access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 69 citations in OpenAlex.
- Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study.Scientific reports · 2022Trial
- Trial
- Endocannabinoids and related lipids in host metabolism-gut microbiome signalling.Nature reviews. Endocrinology · 2026Review
- Intestinal colonization of germ-free mice with indole-producing E. coli modulates the central and peripheral endocannabinoidome.Journal of lipid research · 2026Article
- Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Breaking down barriers: is intestinal mucus degradation byInfection and immunity · 2025Review
- The endocannabinoidome-gut microbiome-brain axis as a novel therapeutic target for autism spectrum disorder.Journal of biomedical science · 2025Review
- Fecal Dysosmobacter spp. concentration is linked to plasma lipidome in insulin-resistant individuals with overweight, obesity and metabolic syndrome.Lipids in health and disease · 2025Article
- The Human Fecal Endocannabinoidome Mediator Profile Is Mainly Defined by the Fecal Microbiota and Diet.The Journal of clinical endocrinology and metabolism · 2025Article
- Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.Frontiers in immunology · 2025Review
- Mice deficient in the phosphatase activity of sEH show decreased levels of the endocannabinoid 2-AG in the olfactory bulb and depressive-like behavior.FEBS letters · 2024Article
- Article
- The influence of Akkermansia muciniphila on intestinal barrier function.Gut pathogens · 2024Review
- A Possible Role of Akkermansia muciniphila in the Treatment of Olanzapine-Induced Weight Gain.Cureus · 2024Review
- Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment.International journal of molecular sciences · 2024Review
- ProbioticNutrients · 2024Article
- Article
- Contribution of the microbiome for better phenotyping of people living with obesity.Reviews in endocrine & metabolic disorders · 2023Review
- Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.Pharmacological reviews · 2023Review
- Hypoabsorptive surgeries cause limb-dependent changes in the gut endocannabinoidome and microbiome in association with beneficial metabolic effects.International journal of obesity (2005) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 5 countries.
Clara DepommierMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Université Catholique de Louvain, Av. E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium.
Rosa Maria VitaleEndocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli, Italy.ORCID 0000-0001-9243-1307
Fabio Arturo IannottiEndocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli, Italy.ORCID 0000-0003-4480-8370
Cristoforo SilvestriQuebec Heart and Lung Institute Research Centre, Université Laval, Quebec City, QC G1V 0A6, Canada.ORCID 0000-0001-5635-1545
Nicolas FlamandQuebec Heart and Lung Institute Research Centre, Université Laval, Quebec City, QC G1V 0A6, Canada.ORCID 0000-0001-5944-7200
Céline DruartMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Université Catholique de Louvain, Av. E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium.
Amandine EverardMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Université Catholique de Louvain, Av. E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium.
Rudy PelicaenMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Université Catholique de Louvain, Av. E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium.ORCID 0000-0002-0890-6320
Dominique MaiterPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0002-0918-637X
Jean-Paul ThissenPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, 1200 Brussels, Belgium.
Audrey LoumayePôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, 1200 Brussels, Belgium.
Michel P HermansPôle EDIN, Institut de Recherches Expérimentales et Cliniques, UCLouvain, Université catholique de Louvain, 1200 Brussels, Belgium.
Nathalie M DelzenneMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Université Catholique de Louvain, Av. E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium.ORCID 0000-0003-2115-6082
Willem M de VosLaboratory of Microbiology, Wageningen University, 6708WE Wageningen, The Netherlands.ORCID 0000-0002-0273-3166
Vincenzo Di MarzoEndocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli, Italy.
Patrice D CaniMetabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Université Catholique de Louvain, Av. E. Mounier, 73 B1.73.11, 1200 Brussels, Belgium.ORCID 0000-0003-2040-2448
Walloon Excellence in Lifesciences and Biotechnology · BECliniques Universitaires Saint-Luc · BENational Research Council · ITUniversité Laval · CAUniversity of Helsinki · FI
Funding
CIHR
Abstract
PubMed holds no abstract for this paper.
Indexed as
Metabolic SyndromeObesityPPAR alphaAdultAkkermansiaAnimalsChlorocebus aethiopsCOS CellsEndocannabinoidsFemaleHumansMaleMonoglyceridesEndocannabinoidsMonoglyceridesPPAR alphaPPARA protein, humanAkkermansia muciniphilaendocannabinoidomeendocannabinoidshumanmetabolic syndromemono-palmitoyl-glycerolobesityperoxisome proliferator-activated receptor alpha (PPARα)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.